Sign in Subscribe
Pharmaceutical industry

Vioxx Trial Exposes Hidden Risks: A Catalyst for Change in Pharmaceutical Research

Strategic Insights

— 1 min read

Renée Montagne and Snigdha Prakash report on the first trial of a wrongful death case against Merck, drugmaker of Vioxx, a painkiller pulled from the market in 2004 due to cardiovascular risks. The plaintiffs will argue that Merck knew about the risks but hid them from doctors and patients. The trial highlights the importance of transparency in pharmaceutical research, exposing flaws in the scientific study published in The New England Journal of Medicine in 2000.

Key Takeaways:

  • The 2000 study published in The New England Journal of Medicine claimed Vioxx was safe for the heart, contradicting the plaintiffs' argument that Merck knew about the risks.
  • Critic cardiologist Eric Topol says the study was misleading, twisting the data to show Vioxx's benefits rather than its risks.
  • Topol reanalyzed the VIGOR data using additional numbers from the FDA and different statistical methods, concluding that Vioxx doubled a patient's risk for cardiovascular problems.
  • The New England Journal's editor, Jeffrey Drazen, defends the publication of the paper, citing the data available at the time and the paper's rigorous review process.
  • Ted Mayer, a lawyer representing Merck, argues that the paper accurately disclosed the information from the VIGOR trial and that the additional data submitted to the FDA did not change the overall conclusions.
  • Snigdha Prakash reports that Merck didn't make the company scientists who wrote the paper available for an interview, and the lead authors declined to be interviewed.

Statistics:

  • 3,000: The number of wrongful death and injury suits filed against Merck in the United States.
  • 2000: The year The New England Journal of Medicine published the study on Vioxx's safety.
  • 2001: The year Eric Topol reanalyzed the VIGOR data and published the results in the Journal of the American Medical Association.
  • 2,700: The word count of the article published in The New England Journal of Medicine.
  • 5-fold: The increase in heart attacks in the VIGOR trial, which Eric Topol says was ignored in the original study.

Sources:

  • "Host:Opening statements are beginning this morning in Angleton, Texas, in the first trial of a wrongful death case brought by the family of a Vioxx user." - Renée Montagne (IdRef="1")
  • Snigdha Prakash, NPR News, reporting on the Vioxx trial and the critical examination of the 2000 study published in The New England Journal of Medicine.

Read more